Proactive CRS Management: The Role of Tocilizumab and Beyond

Author(s):

Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.

EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

Now Viewing

EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond

EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

Video content above is prompted by the following:

Data from ASH 2024 suggest intravenous immunoglobulin (IVIG) can play a critical role in preventing infections in patients receiving teclistamab. How do you incorporate IVIG into your clinical practice, and what considerations guide its use?
Beyond IVIG, what additional strategies or prophylactic measures have you incorporated into your practice to reduce infection risk in patients on bispecific antibody therapies in multiple myeloma?
Cytokine release syndrome (CRS) remains a common concern with bispecific antibodies. What strategies do you find most effective for managing CRS?